Amendis appoints Ron Mayron to the Position of Chairman
Ron Mayron has a rich experience in the pharmaceutical and medical equipment industry, having served for over 20 years in several key positions and senior management positions in the field of pharmaceuticals in the local and global market, his former
Amendis successfully completed its first clinical study on oral cavity cancer patients to predict metastasis to the neck.
As part of the clinical study, which was conducted at the Hadassah University Hospital-Ein Kerem under Helsinki approval, cancerous tissues from the tongue of head and neck cancer patients were examined. Amendis’s proprietary AI based technology was used to predict
Amendis will start a limited validation study of its predictive diagnostic test based on actual cases
Amendis, whose primary objective is to minimize unnecessary surgery on neck cancer patients, has announced that it is initiating a limited validation study of its predictive diagnostic test based on actual cases. At present, following a diagnosis of throat cancer,
Amendis signed a commercialization agreement with Yissum
Amendis has signed an Exclusive License Agreement with Yissum, the technology transfer company of The Hebrew University of Jerusalem. The company, in collaboration with researchers from the Hebrew University in Jerusalem, developed a system based on a Self Learning